Mr. Nick Kadysh reports

PHARMALA BIOTECH REGISTERS TRADEMARK FOR MDMA

Pharmala Biotech Holdings Inc. has registered a trademark for its clinical-grade MDMA (3,4-methylenedioxymethamphetamine) product, which shall be marketed as Laneo MDMA. Pharmala is currently the only publicly traded company to have developed a full manufacturing value chain for MDMA.

"While MDMA is a generic drug, there's a huge difference between illicit drug manufacture and our clinical-grade product. Only one is appropriate for use in scientific research: Laneo MDMA," said Nick Kadysh, chief executive officer of Pharmala Biotech. "With this trademark registration, Pharmala continues to establish itself as the leader in MDMA manufacture, research and development."

A number of customers have already made deposits for Laneo MDMA, and the company anticipates initial product deliveries to be made in fall of 2022. Laneo MDMA is initially available to customers in both a 40-milligram formulated clinical trial capsule and as pure active pharmaceutical ingredient (API) which can be compounded by a qualified pharmacist. In the future, a range of drug product formulations can be developed.

"We're speaking to customers every day who are excited to initiate clinical trials with MDMA -- but they are unable to do so because up until now, they didn't have access to clinical trial supply of drug product," said David Purcell, director of sales at Pharmala Biotech. "Pharmala Biotech's Laneo MDMA is the answer."

About Pharmala Biotech Holdings Inc.

Pharmala Biotech is a biotechnology company focused on the research, development and manufacturing of MDXX-class (substituted methylenedioxyphenethylamine) molecules, including MDMA. Pharmala was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. Pharmala is a regulatory-first organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Its team of dedicated professionals includes regulatory experts, scientists and biomanufacturing professionals. Pharmala has built what it believes to be North America's first cGMP (current good manufacturing practice) MDMA value chain, encompassing GMP manufacturing of active pharmaceutical ingredient (API) and drug product formulation. Pharmala's research and development unit has also begun preclinical research into two patented novel chemical entities (NCEs) based on MDXX-class molecules, with proof-of-concept research currently continuing at the University of Arkansas School for Medical Sciences in the United States and at InterVivo Solutions in Canada.

We seek Safe Harbor.